![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Takeda Global Research & Development Center, Inc. |
---|---|
Information provided by: | Takeda Global Research & Development Center, Inc. |
ClinicalTrials.gov Identifier: | NCT00591578 |
The purpose of this study is to compare the efficacy of TAK-491 to valsartan with reducing systolic blood pressure in subjects with essential hypertension.
Condition | Intervention | Phase |
---|---|---|
Essential Hypertension |
Drug: TAK-491 Drug: Valsartan |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension |
Estimated Enrollment: | 810 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: TAK-491
TAK-491 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
|
2: Experimental |
Drug: TAK-491
TAK-491 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
|
3: Active Comparator |
Drug: Valsartan
Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
|
Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization (WHO), hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.
This study is being conducted to determine whether administration of TAK-491 in subjects with essential hypertension is more efficacious in reducing systolic blood pressure than valsartan.
Study participation is anticipated to be approximately 7 months. Outside of the study center, participants will be required to wear an ambulatory blood pressure monitoring device at 24 hour intervals.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
Contact: Takeda Study Registration Call Center | 1+800-778-2860 | medicalinformation@tpna.com |
Study Director: | Executive Medical Director Clinical Science | Takeda Global Research & Development Center, Inc. |
Responsible Party: | Takeda Global Research & Development Center, Inc. ( Sr. VP, Clinical Science ) |
Study ID Numbers: | TAK-491_301 |
Study First Received: | December 27, 2007 |
Last Updated: | February 16, 2009 |
ClinicalTrials.gov Identifier: | NCT00591578 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Blood pressure; blood pressure monitoring, ambulatory |
Essential Hypertension Vascular Diseases Cardiovascular Agents |
Antihypertensive Agents Valsartan Hypertension |
Therapeutic Uses Vascular Diseases Cardiovascular Diseases Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Valsartan Hypertension |